Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 19Terminated 3Unknown 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 66Other hematologic neoplasm 26Sarcoma 7CNS 6Plasma cell 3Myeloid 3Dermatologic 2Thoracic 1Other solid neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 3Recurrence 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Vincristine × Plasma cell × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT00215943 2014-04-17

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

H. Lee Moffitt Cancer Center and Research Institute

Phase 3 Terminated
90 enrolled 10 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00441168 2014-03-21

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Janssen-Cilag International NV

Phase 2 Terminated
30 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡